Biological heterogeneity in children with moderate asthma and correlation with exacerbations
R. Gagliardo, S. La Grutta, F. Mirabella, P. Abate, G. B. Pajno, G. Bonsignore, A. M. Vignola (Palermo, Italy)
Source: Annual Congress 2002 - The role of inflammatory markers in children with asthma
Session: The role of inflammatory markers in children with asthma
Session type: Thematic Poster Session
Number: 932
Disease area: Airway diseases
Abstract The identification of biomarkers to be measured in a non-invasive manner represents an important goal in the management of asthma in both children and adults. We then undertook a study to identify inflammatory bio-markers in PBMC of untreated intermittent asthmatic (IA) and moderate asthmatic (MA) children, clinically stable and treated with fluticasone propionate 250mg twice a day. We evaluated IL-8 and GMCSF release by PBMC isolated from control children (C), IA and MA, and exhaled NO (FENO) at baseline. In addition we evaluated, by Western Blot, the expression of p65 and phosphorylated IkBa. GMCSF and IL-8 release were similar in IA and MA and significantly higher than in C. FENO levels were higher in IA and MA than in C, but not statistically different. Within MA were observed two distinct subgroups according to GMCSF and IL-8 production, and FENO. These parameters were significantly correlated with the number of exacerbations during 18 months follow up period. The amount of p65 and p-IkBa protein was higher in MA than that of IA and C. This study suggests that enhanced IL-8 and GMCSF release in MA may be due to increased NF-kB pathway activation; in addition the sustained inflammation in MA, provides evidences for a subpopulation in moderate asthmatic children with different levels of inflammatory biomarkers.
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Gagliardo, S. La Grutta, F. Mirabella, P. Abate, G. B. Pajno, G. Bonsignore, A. M. Vignola (Palermo, Italy). Biological heterogeneity in children with moderate asthma and correlation with exacerbations. Eur Respir J 2002; 20: Suppl. 38, 932
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Genetic comparison between severe persistent asthma and COPD Source: Eur Respir J 2003; 22: Suppl. 45, 81s Year: 2003
Ventilation heterogeneity in children with severe asthma Source: International Congress 2017 – Diagnostic tools and comorbidities in paediatric asthma Year: 2017
Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017
What are the differences between moderate and severe COPD exacerbation groups? Source: International Congress 2019 – Airway disease-associated exacerbations Year: 2019
Relationship between benralizumab exposure and asthma exacerbation rate for patients with severe asthma Source: International Congress 2017 – Asthma: mechanisms and treatment Year: 2017
Predictors of severe exacerbations in patients with moderate and severe asthma Source: International Congress 2018 – Determinants and monitoring of asthma control Year: 2018
Impact of the eosinophil variability on severe exacerbations in an asthmatic population Source: Virtual Congress 2020 – Severe asthma phenotypes and outcomes Year: 2020
The association between airway and systemic eosinophilia and symptoms and exacerbations differ between asthma and COPD patients Source: Virtual Congress 2020 – Monitoring of inflammation in remodelling Year: 2020
Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005
The correlation between asthma severity and rhinitis severity Source: Eur Respir J 2002; 20: Suppl. 38, 45s Year: 2002
Clinical phenotypic differences between COPD and asthma in elderly patients Source: Eur Respir J 2004; 24: Suppl. 48, 60s Year: 2004
Incidence of COPD and asthma overlap Source: Annual Congress 2009 - Asthma assessment and original therapeutic approaches Year: 2009
Additional value of spirometry in risk assessment of acute respiratory disease in winter among patients with mild to moderate asthma or COPD Source: Eur Respir J 2002; 20: Suppl. 38, 473s Year: 2002
The longitudinal association of daily physical activity and symptoms of exacerbations in COPD patients Source: International Congress 2017 – Best abstracts in physical activity and management of COPD Year: 2017
Distribution of biomarkers in severe asthma and severe uncontrolled asthma Source: Virtual Congress 2021 – Pearls in asthma and respiratory burden research Year: 2021
Risk factors for moderate exacerbations in childhood asthma Source: Eur Respir J 2004; 24: Suppl. 48, 163s Year: 2004
COPD patients with asthma, characteristics and risk of exacerbations Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD Year: 2019
The ERS/EAACI statement on severe exacerbations of asthma, and how to deal with non-allergic severe asthma Source: International Congress 2019 – Pathophysiology and clinical insights into severe non-allergic asthma Year: 2019
Physical status and dependence levels in patients with COPD exacerbation Source: International Congress 2014 – Physical activity, exercise and physiotherapy in patients with COPD Year: 2014